Chikungunya

Why Valneva CEO remains bullish on Pfizer-partnered Lyme vaccine

Despite a phase 3 miss and a difficult regulatory environment, Valneva and Pfizer remain hopeful about scoring an approval for their Lyme disease shot.

Angus Liu Apr 1, 2026 3:00pm

Man hands gold dollar sign to another man

Fierce Pharma

Bavarian Nordic's $160M PRV price reflects new realities

Jun 18, 2025 11:47am

christmas cash gift money present holiday

Valneva sells priority review voucher for $103M, R&D to benefit

Feb 5, 2024 9:15am

FDA delays decision on Valneva's chikungunya vaccine by 3 months

Aug 14, 2023 6:00am

On target clinical trial success bullseye score

Bavarian Nordic goes 2 for 2 in key chikungunya vaccine trials

Aug 7, 2023 5:40am

Bavarian Nordic chikungunya vaccine hits primary goal in phase 3

Jun 20, 2023 9:00am